Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

Bibliographic Details
Main Authors:	Jan Maurik van den Heuvel, Niloufar Farzan, Anke-Hilse Maitland-van der Zee, Fariba Ahmadizar
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-04-01
Series:	BMJ Open Diabetes Research & Care
Online Access:	https://drc.bmj.com/content/8/1/e000705corr1.full

Similar Items

Mining treatment patterns of glucose-lowering medications for type 2 diabetes in the Netherlands
by: Jan Maurik van den Heuvel, et al.
Published: (2020-04-01)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
by: Ildiko Lingvay, et al.
Published: (2020-11-01)

Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Fang-Hong Shi, et al.
Published: (2018-06-01)

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events
by: Thomas Hansen, et al.
Published: (2020-12-01)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
by: Hassan A. Alsugair, et al.
Published: (2021-08-01)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
by: Lyndon Marc Evans, et al.
Published: (2021-07-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Semaglutide-associated bullous pemphigoid
by: Clayton P. Burruss, BS, et al.
Published: (2021-09-01)

The Dutch in New Netherland
by: H. van der Zee, et al.
Published: (1982-01-01)

The Dutch in New Netherland
by: H. van der Zee, et al.
Published: (1982-01-01)

The Dutch in New Netherland
by: H. van der Zee, et al.
Published: (1982-01-01)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
by: Lawrence A. Leiter, et al.
Published: (2019-06-01)

Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
by: Fariba Ahmadizar, et al.
Published: (2015-01-01)

Acute Kidney Injury Associated With Semaglutide
by: David J. Leehey, et al.
Published: (2021-03-01)

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
by: Ann Mertens, et al.
Published: (2020-12-01)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
by: Juris J. Meier
Published: (2021-06-01)

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes
by: Chapman, R.H, et al.
Published: (2021)

Nonsurgical Corrective Union of Osteoporotic Vertebral Fracture with Once-Weekly Teriparatide
by: Naohisa Miyakoshi, et al.
Published: (2015-01-01)

Higher prescription of antidepressants and/or anxiolytics among chronic obstructive pulmonary disease patients
by: Charlotte E. Pelgrim, et al.
Published: (2021-03-01)

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
by: Abramson, Alex, et al.
Published: (2022)

Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide
by: Abramson, Alex, et al.
Published: (2022)

Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)

Farmakologisk behandling vid fetma : Semaglutid versus liraglutid
by: Nilsson, Natalié
Published: (2021)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
by: Baptist Gallwitz, et al.
Published: (2021-06-01)

Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
by: Fariba Ahmadizar, et al.
Published: (2015-01-01)

Comparison of different dosing regimens (once weekly <it>vs</it>. twice weekly, and once weekly <it>vs</it>. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
by: Macdougall Iain C
Published: (2007-11-01)

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China
by: Shanshan Hu, et al.
Published: (2021-06-01)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
by: Michael E Røder
Published: (2019-12-01)

Effect of once weekly oral levothyroxine therapy
by: Andrea del Toro-Diez, et al.
Published: (2021-07-01)

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands
by: J. M. van den Heuvel, et al.
Published: (2018-04-01)

The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
by: Bruce Wang, et al.
Published: (2015-01-01)

Exenatide once weekly: clinical outcomes and patient satisfaction
by: Biju Jose1, et al.
Published: (2010-08-01)

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
by: Xin Zhang, et al.
Published: (2021-07-01)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
by: Pearson S, et al.
Published: (2019-12-01)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
by: Gomez-Peralta F, et al.
Published: (2019-02-01)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes
by: Rafael Simó, et al.
Published: (2021-07-01)

Incremental and Once- to Twice-Weekly Hemodialysis: From Experience to Evidence
by: Yoshitsugu Obi, et al.
Published: (2017-09-01)

Effects of Exenatide Twice Daily and Once Weekly on Weight Loss
by: Patel, Rajal, et al.
Published: (2013)

Costs in the Last Year of Life in the Netherlands
by: Tom Stooker, et al.
Published: (2001-02-01)